Multinational pharmaceutical company sees Chinese innovative pharmaceutical company Novartis announces acquisition of Sinopharm Pharmaceuticals
王俊杰2017
发表于 2024-1-6 19:00:41
215
0
0
Recently, multinational pharmaceutical giant Novartis announced an agreement to acquire Sinovac Pharmaceuticals, strengthening its presence in the field of kidney disease.
Xinruinuo Pharmaceuticals is a clinical stage Chinese biotechnology company specializing in the field of kidney disease and related treatments, established in 2021. After the transaction is completed, the pharmaceutical company will be integrated into Novartis China as a whole. Novartis announced in a statement that this acquisition is expected to expand the company's kidney disease product portfolio in China, enrich future product lines, and better meet the treatment needs of kidney disease patients in China.
It is reported that Xinruinuo Pharmaceutical's core assets include two drugs in the clinical development stage, namely atrasentan and zigakibart (BION-1301), both used for the treatment of IgA nephropathy. IgA nephropathy is a progressive kidney disease that mainly affects young people, and currently targeted treatment options are limited. Xinruinuo Pharmaceutical has the exclusive right to develop and commercialize these two assets in the Asian region.
Zhang Ying, President and Managing Director of Novartis China, publicly stated that the agreement is fully aligned with Novartis's strategy of focusing on innovative drugs in four core treatment areas, including cardiovascular, renal and metabolic, immune, neuroscience, and oncology. After integration, Novartis will leverage its experience in drug development and commercialization to accelerate the commercial launch of Xinruinuo Pharmaceutical's research product line, providing assistance to kidney disease patients in need.
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- Johnson&Johnson China CEO Song Weiqun steps down as Chairman of Johnson&Johnson China
- Liu Wenjuan appointed as CEO of Starbucks China
- Starbucks adjusts leadership structure in China, with Liu Wenjuan appointed as CEO of Starbucks China
- Starbucks China changes its style! Liu Wenjuan appointed as CEO to tackle challenges of declining performance
- Be optimistic about the Chinese stock market! Foreign institutions gradually issue Chinese stock funds to buy A-shares at the bottom
- NIO and Sinopec reach charging service cooperation agreement
- NIO and Sinopec reach charging service cooperation agreement
- 28 productions from iQiyi have been shortlisted for the 34th China TV Drama "Flying Apsaras Award"
- Yum China and Poly Developments Establish Strategic Partnership
- Ye Guofu re imagines the future of Chinese retail
-
9月が終わり、映画・テレビ業界が暗躍している。最近、愛奇芸の創始者でCEOのGONG宇氏は、映画・テレビ業界が長短の変化、AIの変化、中国映画・テレビドラマの海外進出の変化の3つの変化を経験していると発表した。 ...
- 寒郁轩良
- 昨天 14:17
- 支持
- 反对
- 回复
- 收藏
-
8月のトヨタ自動車(ダイハツ自動車と日野自動車を除く、レクサスを含む)の世界生産台数は前年同月比11.2%減の709571台、世界販売台数は前年同月比3.1%減の826863台だった。 日本本土市場では、トヨタ自動車の8月 ...
- SOGO
- 3 天前
- 支持
- 反对
- 回复
- 收藏
-
ネットワーク状況監視サイトDownDetectorによると、オーディオストリーミングプラットフォームSpotifyは日曜日に約3時間にわたる障害を経験した後、正常に回復し、ピーク時には米国の4万人以上のユーザーに影響を与 ...
- hecgdge4
- 昨天 09:33
- 支持
- 反对
- 回复
- 收藏
-
百済神州(688235.SH)はA株の有名な革新薬企業で、2017-2024年上半期、同社の各期の研究開発投資はA株の化学製薬会社(申万二級)の中で最も高く、研究開発費用は合計600億元を超えた。 しかし、百済神州にとって ...
- wylz8473
- 前天 18:36
- 支持
- 反对
- 回复
- 收藏